Boston Scientific (NYSE:BSX) CEO Purchases $9,000,979.20 in Stock

Boston Scientific Corporation (NYSE:BSX) CEO Michael Mahoney bought 186,240 shares of the stock in a transaction on Monday, August 3rd. The stock was purchased at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the acquisition, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. This trade represents a 13.27% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Boston Scientific Trading Up 0.1%

Boston Scientific stock opened at $49.35 on Friday. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50. The company has a market cap of $71.53 billion, a P/E ratio of 19.98, a P/E/G ratio of 1.08 and a beta of 0.56. The company has a quick ratio of 1.22, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The business has a 50-day simple moving average of $45.75 and a two-hundred day simple moving average of $60.73.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The company had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm’s revenue was up 7.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific announced that its Board of Directors has approved a share repurchase program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s leadership believes its stock is undervalued.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Group LLC bought a new stake in Boston Scientific during the fourth quarter valued at about $28,064,000. Meiji Yasuda America Inc bought a new position in Boston Scientific in the fourth quarter worth about $4,708,000. Harvest Portfolios Group Inc. raised its holdings in Boston Scientific by 6.1% in the fourth quarter. Harvest Portfolios Group Inc. now owns 597,341 shares of the medical equipment provider’s stock worth $56,956,000 after purchasing an additional 34,598 shares in the last quarter. LBP AM SA lifted its position in shares of Boston Scientific by 8.4% during the fourth quarter. LBP AM SA now owns 434,393 shares of the medical equipment provider’s stock valued at $41,419,000 after buying an additional 33,534 shares during the last quarter. Finally, William Blair Investment Management LLC purchased a new stake in shares of Boston Scientific during the fourth quarter valued at about $4,914,000. Institutional investors own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on BSX. The Goldman Sachs Group set a $71.00 price objective on Boston Scientific in a research note on Thursday, May 28th. Robert W. Baird set a $56.00 price target on shares of Boston Scientific in a report on Thursday, July 30th. Wolfe Research lowered shares of Boston Scientific from an “outperform” rating to a “peer perform” rating in a research report on Friday, May 29th. Barclays reduced their price objective on shares of Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a research note on Thursday, May 28th. Finally, Citigroup lowered their target price on shares of Boston Scientific from $70.00 to $61.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Twenty-four research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Boston Scientific has a consensus rating of “Moderate Buy” and an average target price of $71.62.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.